May 29, 2023
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
May 25, 2023
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
May 24, 2023
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
May 16, 2023
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
